Full Text:   <363>

Summary:  <201>

CLC number: 

On-line Access: 2024-02-01

Received: 2023-06-25

Revision Accepted: 2023-09-07

Crosschecked: 2024-02-02

Cited: 0

Clicked: 439

Citations:  Bibtex RefMan EndNote GB/T7714


Xiangyu HONG


Caiyun FU


-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2024 Vol.25 No.2 P.91-105


Advances in the research and application of neurokinin-1 receptor antagonists

Author(s):  Xiangyu HONG, Junjie MA, Shanshan ZHENG, Guangyu ZHAO, Caiyun FU

Affiliation(s):  College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China

Corresponding email(s):   fucy03@zstu.edu.cn

Key Words:  Neurokinin-1 receptor (NK-1R) antagonist, Pathophysiological disorder, Tumor target, Bioavailability, Nanoencapsulation, Synergistic therapy

Share this article to: More |Next Article >>>

Xiangyu HONG, Junjie MA, Shanshan ZHENG, Guangyu ZHAO, Caiyun FU. Advances in the research and application of neurokinin-1 receptor antagonists[J]. Journal of Zhejiang University Science B, 2024, 25(2): 91-105.

@article{title="Advances in the research and application of neurokinin-1 receptor antagonists",
author="Xiangyu HONG, Junjie MA, Shanshan ZHENG, Guangyu ZHAO, Caiyun FU",
journal="Journal of Zhejiang University Science B",
publisher="Zhejiang University Press & Springer",

%0 Journal Article
%T Advances in the research and application of neurokinin-1 receptor antagonists
%A Xiangyu HONG
%A Junjie MA
%A Shanshan ZHENG
%A Guangyu ZHAO
%A Caiyun FU
%J Journal of Zhejiang University SCIENCE B
%V 25
%N 2
%P 91-105
%@ 1673-1581
%D 2024
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2300455

T1 - Advances in the research and application of neurokinin-1 receptor antagonists
A1 - Xiangyu HONG
A1 - Junjie MA
A1 - Shanshan ZHENG
A1 - Guangyu ZHAO
A1 - Caiyun FU
J0 - Journal of Zhejiang University Science B
VL - 25
IS - 2
SP - 91
EP - 105
%@ 1673-1581
Y1 - 2024
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2300455

Recently, the substance P (SP)/neurokinin-1 receptor (NK-1R) system has been found to be involved in various human pathophysiological disorders including the symptoms of coronavirus disease 2019 (COVID-19). Besides, studies in the oncological field have demonstrated an intricate correlation between the upregulation of NK-1R and the activation of SP/NK-1R system with the progression of multiple carcinoma types and poor clinical prognosis. These findings indicate that the modulation of SP/NK-1R system with NK-1R antagonists can be a potential broad-spectrum antitumor strategy. This review updates the latest potential and applications of NK-1R antagonists in the treatment of human diseases and cancers, as well as the underlying mechanisms. Furthermore, the strategies to improve the bioavailability and efficacy of NK-1R antagonist drugs are summarized, such as solid dispersion systems, nanonization, and nanoencapsulation. As a radiopharmaceutical therapeutic, the NK-1R antagonist aprepitant was originally developed as radioligand receptor to target NK-1R-overexpressing tumors. However, combining NK-1R antagonists with other drugs can produce a synergistic effect, thereby enhancing the therapeutic effect, alleviating the symptoms, and improving patients’ quality of life in several diseases and cancers.




Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article


[1]AfshariAR, Motamed-SanayeA, SabriH, et al., 2021. Neurokinin-1 receptor (NK-1R) antagonists: potential targets in the treatment of glioblastoma multiforme. Curr Med Chem, 28(24):4877-4892.

[2]AgelopoulosK, RülanderF, DangelmaierJ, et al., 2019. Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1/2 activation. J Eur Acad Dermatol Venereol, 33(12):2371-2379.

[3]AlwazzanA, MehboobR, HassanA, et al., 2020. Elevated neurokinin-1 receptor expression in uterine products of conception is associated with first trimester miscarriages. Front Physiol, 11:554766.

[4]BaiTR, ZhouD, WeirT, et al., 1995. Substance P (NK1)- and neurokinin A (NK2)-receptor gene expression in inflammatory airway diseases. Am J Physiol, 269(3 Pt 1):L309-L317.

[5]BakirtziK, LawIKM, FangK, et al., 2019. MiR-21 in substance P-induced exosomes promotes cell proliferation and migration in human colonic epithelial cells. Am J Physiol, 317(6):G802-G810.

[6]BarbeMF, HilliardBA, FisherPW, et al., 2020. Blocking substance P signaling reduces musculotendinous and dermal fibrosis and sensorimotor declines in a rat model of overuse injury. Connect Tissue Res, 61(6):604-619.

[7]BeirithI, RenzBW, MudusettiS, et al., 2021. Identification of the neurokinin-1 receptor as targetable stratification factor for drug repurposing in pancreatic cancer. Cancers (Basel), 13(11):2703.

[8]BiadseeA, BiadseeA, KassemF, et al., 2020. Olfactory and oral manifestations of COVID-19: sex-related symptoms—a potential pathway to early diagnosis. Otolaryngol Head Neck Surg, 163(4):722-728.

[9]BubakAN, ComoCN, BlackmonAM, et al., 2018. Varicella zoster virus induces nuclear translocation of the neurokinin-1 receptor, promoting lamellipodia formation and viral spread in spinal astrocytes. J Infect Dis, 218(8):1324-1335.

[10]ChenY, ChauhanSK, LeeHS, et al., 2014. Chronic dry eye disease is principally mediated by effector memory TH17 cells. Mucosal Immunol, 7(1):38-45.

[11]ChuHW, KraftM, KrauseJE, et al., 2000. Substance P and its receptor neurokinin 1 expression in asthmatic airways. J Allergy Clin Immunol, 106(4):713-722.

[12]CraigVJ, ZhangL, HagoodJS, et al., 2015. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol, 53(5):585-600.

[13]de FelipeC, HerreroJF, O'BrienJA, et al., 1998. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature, 392(6674):394-397.

[14]Definition and Classification Subcommittee, 2007. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf, 5(2):75-92.

[15]DehlinHM, LevickSP, 2014. Substance P in heart failure: the good and the bad. Int J Cardiol, 170(3):270-277.

[16]DengXT, TangSM, WuPY, et al., 2019. SP/NK-1R promotes gallbladder cancer cell proliferation and migration. J Cell Mol Med, 23(12):7961-7973.

[17]DongJQ, FengF, XuGH, et al., 2015. Elevated SP/NK-1R in esophageal carcinoma promotes esophageal carcinoma cell proliferation and migration. Gene, 560(2):205-210.

[18]DongYY, MoX, HuYB, et al., 2020. Epidemiology of COVID-19 among children in China. Pediatrics, 145(6):e20200702.

[19]DouglasSD, LeemanSE, 2011. Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann N Y Acad Sci, 1217:83-95.

[20]EbrahimiS, JavidH, AlaeiA, et al., 2020. New insight into the role of substance P/neurokinin-1 receptor system in breast cancer progression and its crosstalk with microRNAs. Clin Genet, 98(4):322-330.

[21]EbrahimiS, MirzaviF, Aghaee-BakhtiariSH, et al., 2022. SP/NK1R system regulates carcinogenesis in prostate cancer: shedding light on the antitumoral function of aprepitant. Biochim Biophys Acta Mol Cell Res, 1869(5):119221.

[22]FoulshamW, MarmalidouA, AmouzegarA, et al., 2017. Review: the function of regulatory T cells at the ocular surface. Ocul Surf, 15(4):652-659.

[23]García-ArandaM, TéllezT, McKennaL, et al., 2022. Neurokinin-1 receptor (NK-1R) antagonists as a new strategy to overcome cancer resistance. Cancers (Basel), 14(9):2255.

[24]GeCT, HuangHM, HuangFY, et al., 2019. Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload. Proc Natl Acad Sci USA, 116(39):19635-19645.

[25]GhahremanlooA, JavidH, AfshariAR, et al., 2021. Investigation of the role of neurokinin-1 receptor inhibition using aprepitant in the apoptotic cell death through PI3K/Akt/NF-κB signal transduction pathways in colon cancer cells. Biomed Res Int, 2021:1383878.

[26]GhasemiA, HashemySI, AghaeiM, et al., 2018. Leptin induces matrix metalloproteinase 7 expression to promote ovarian cancer cell invasion by activating ERK and JNK pathways. J Cell Biochem, 119(2):2333-2344.

[27]GhasemiA, SaeidiJ, Azimi-NejadM, et al., 2019. Leptin-induced signaling pathways in cancer cell migration and invasion. Cell Oncol (Dordr), 42(3):243-260.

[28]GordonL, PolakJM, MoscosoGJ, et al., 1993. Development of the peptidergic innervation of human heart. J Anat, 183(Pt 1):131-140.

[29]HalikPK, LipińskiPFJ, MatalińskaJ, et al., 2020. Radiochemical synthesis and evaluation of novel radioconjugates of neurokinin 1 receptor antagonist aprepitant dedicated for NK1R-positive tumors. Molecules, 25(16):3756.

[30]HalikPK, KoźmińskiP, MatalińskaJ, et al., 2022. In vitro biological evaluation of aprepitant based 177Lu-radioconjugates. Pharmaceutics, 14(3):607.

[31]IsornaI, EstebanF, SolanellasJ, et al., 2020. The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study. Eur J Histochem, 64(2):3117.

[32]JinP, QiDQ, CuiYH, et al., 2022. Aprepitant attenuates NLRC4-dependent neuronal pyroptosis via NK1R/PKCδ pathway in a mouse model of intracerebral hemorrhage. J Neuroinflammation, 19:198.

[33]KakadeP, PathanZ, GiteS, et al., 2022. Nanoparticle engineering of aprepitant using Nano-by-Design (NbD) approach. AAPS PharmSciTech, 23(6):204.

[34]KastRE, RamiroS, LladóS, et al., 2016. Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. J Neurooncol, 126(3):425-431.

[35]KhomS, SteinkellnerT, HnaskoTS, et al., 2020. Alcohol dependence potentiates substance P/neurokinin-1 receptor signaling in the rat central nucleus of amygdala. Sci Adv, 6(12):eaaz1050.

[36]KhorasaniS, BoroumandN, Lavi ArabF, et al., 2020. The immunomodulatory effects of tachykinins and their receptors. J Cell Biochem, 121(5-6):3031-3041.

[37]KimRY, SunkaraKP, BrackeKR, et al., 2021. A microRNA-21-mediated SATB1/S100A9/NF-‍κB axis promotes chronic obstructive pulmonary disease pathogenesis. Sci Transl Med, 13(621):eaav7223.

[38]KitchensCA, McDonaldPR, PollackIF, et al., 2009. Synergy between microtubule destabilizing agents and neurokinin 1 receptor antagonists identified by an siRNA synthetic lethal screen. FASEB J, 23(S1):756.13-756.13.

[39]KorfiF, JavidH, Assaran DarbanR, et al., 2021. The effect of SP/NK1R on the expression and activity of catalase and superoxide dismutase in glioblastoma cancer cells. Biochem Res Int, 2021:6620708.

[40]KramerMS, CutlerN, FeighnerJ, et al., 1998. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 281(5383):1640-1645.

[41]KumarS, GuptaSK, 2013. Pharmaceutical solid dispersion technology: a strategy to improve dissolution of poorly water-soluble drugs. Recent Pat Drug Deliv Formul, 7(2):111-121.

[42]LeeKS, LeeJ, KimHK, et al., 2021. Extracellular vesicles from adipose tissue-derived stem cells alleviate osteoporosis through osteoprotegerin and miR-21-5p. J Extracell Vesicles, 10(12):e12152.

[43]LiuJW, ZouMJ, PiaoHY, et al., 2015. Characterization and pharmacokinetic study of aprepitant solid dispersions with soluplus®. Molecules, 20(6):11345-11356.

[44]LiuJW, LiSY, AoW, et al., 2022a. Fabrication of an aprepitant nanosuspension using hydroxypropyl chitosan to increase the bioavailability. Biochem Biophys Res Commun, 631:72-77.

[45]LiuJW, LiYJ, AoW, et al., 2022b. Preparation and characterization of aprepitant solid dispersion with HPMCAS-LF. ACS Omega, 7(44):39907-39912.

[46]LiuL, BurcherE, 2005. Tachykinin peptides and receptors: putting amphibians into perspective. Peptides, 26(8):1369-1382.

[47]LiuXP, ZhuYL, ZhengW, et al., 2019. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes. Artif Cells Nanomed Biotechnol, 47(1):1628-1634.

[48]LorestaniS, GhahremanlooA, JangjooA, et al., 2020. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in colorectal cancer. Mol Biol Rep, 47(5):3469-3474.

[49]MaedaH, WuJ, SawaT, et al., 2000. Tumor vascular permeability and the epr effect in macromolecular therapeutics: a review. J Control Release, 65(1-2):271-284.

[50]MahtalN, LenoirO, TinelC, et al., 2022. MicroRNAs in kidney injury and disease. Nat Rev Nephrol, 18(10):643-662.

[51]Maroñas-JiménezL, EstrachT, GallardoF, et al., 2018. Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas. Br J Dermatol, 178(4):e273-e274.

[52]MartinezAN, PhilippMT, 2016. Substance P and antagonists of the neurokinin-1 receptor in neuroinflammation associated with infectious and neurodegenerative diseases of the central nervous system. J Neurol Neuromedicine, 1(2):29-36.

[53]MehboobR, LavezziAM, 2021. Neuropathological explan

[54]ation of minimal COVID-19 infection rate in newborns, infants and children—a mystery so far. New insight into the role of substance P. J Neurol Sci, 420:117276.

[55]MeléndezGC, LiJP, LawBA, et al., 2011. Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells. Cardiovasc Res, 92(3):420-429.

[56]MiaoYB, QuinnTP, 2021. Advances in receptor-targeted radiolabeled peptides for melanoma imaging and therapy. J Nucl Med, 62(3):313-318.

[57]MistrovaE, KruzliakP, DvorakovaMC, 2016. Role of substance P in the cardiovascular system. Neuropeptides, 58:41-51.

[58]MohamedMZ, Abed El BakyMF, AliME, et al., 2022. Aprepitant exerts anti-fibrotic effect via inhibition of TGF-β/Smad3 pathway in bleomycin-induced pulmonary fibrosis in rats. Environ Toxicol Pharmacol, 95:103940.

[59]MohammadiF, JavidH, AfshariAR, et al., 2020. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression. Mol Biol Rep, 47(6):4263-4272.

[60]Molinos-QuintanaA, Trujillo-HachaP, PiruatJI, et al., 2019. Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists. Invest New Drugs, 37:17-26.

[61]MorgatC, MishraAK, VarshneyR, et al., 2014. Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors. J Nucl Med, 55(10):1650-1657.

[62]MozafariM, EbrahimiS, DarbanRA, et al., 2022. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer. Mol Biol Rep, 49(2):1067-1076.

[63]MuñozM, RossoM, 2010. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs, 28(2):187-193.

[64]MuñozM, CoveñasR, 2020a. The neurokinin-1 receptor antagonist aprepitant, a new drug for the treatment of hematological malignancies: focus on acute myeloid leukemia. J Clin Med, 9(6):1659.

[65]MuñozM, CoveñasR, 2020b. The neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer? Cancers, 12(9):2682.

[66]MuñozM, RossoM, Robles-FriasMJ, et al., 2010. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest, 90(8):‍1259-1269.

[67]MuñozM, González-OrtegaA, RossoM, et al., 2012. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists. Peptides, 38(2):318-325.

[68]MuñozM, González-OrtegaA, Salinas-MartínMV, et al., 2014. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer. Int J Oncol, 45(4):1658-1672.

[69]MuñozM, CovenasR, EstebanF, et al., 2015. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. J Biosci, 40(2):441-463.

[70]MuñozM, CrespoJC, CrespoJP, et al., 2019a. Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: a case report. Mol Clin Oncol, 11(1):50-54.

[71]MuñozM, RossoM, CoveñasR, 2019b. Neurokinin-1 receptor antagonists against hepatoblastoma. Cancers (Basel), 11(9):1258.

[72]MuñozM, RossoM, CoveñasR, 2020. Triple negative breast cancer: how neurokinin-1 receptor antagonists could be used as a new therapeutic approach. Mini Rev Med Chem, 20(5):408-417.

[73]MuñozMF, ArgüellesS, RossoM, et al., 2022. The neurokinin-1 receptor is essential for the viability of human glioma cells: a possible target for treating glioblastoma. Biomed Res Int, 2022:6291504.

[74]MuraS, NicolasJ, CouvreurP, 2013. Stimuli-responsive nanocarriers for drug delivery. Nat Mater, 12(11):991-1003.

[75]NizamE, ErinN, 2018. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; effects independent of substance P. Biomed Pharmacother, 108:263-270.

[76]NoronhaV, BhattacharjeeA, PatilVM, et al., 2020. Aprepitant for cough suppression in advanced lung cancer: a randomized trial. Chest, 157(6):1647-1655.

[77]The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Wkly, 2(8):113-122.

[78]OlivieriF, PrattichizzoF, GiulianiA, et al., 2021. miR-21 and miR-146a: the micrornas of inflammaging and age-related diseases. Ageing Res Rev, 70:101374.

[79]OlverI, ShelukarS, ThompsonKC, 2007. Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomedicine, 2(1):13-18.

[80]QuartaraL, AltamuraM, 2006. Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets, 7(8):975-992.

[81]RamanujamD, SchönAP, BeckC, et al., 2021. MicroRNA-21-dependent macrophage-to-fibroblast signaling determines the cardiac response to pressure overload. Circulation, 143(15):1513-1525.

[82]Ramírez-GarcíaPD, RetamalJS, ShenoyP, et al., 2019. A pH-responsive nanoparticle targets the neurokinin 1 receptor in endosomes to prevent chronic pain. Nat Nanotechnol, 14(12):1150-1159.

[83]RattiE, BetticaP, AlexanderR, et al., 2013. Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. J Psychopharmacol, 27(5):424-434.

[84]Reinoso-ArijaR, López-RamírezC, Jimenez-RuizJA, et al., 2021. Effectiveness of aprepitant in post-acute COVID19 syndrome. Clin Case Rep, 9(9):e04646.

[85]RidhurkarDN, AnsariKA, KumarD, et al., 2013. Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties. Drug Dev Ind Pharm, 39(11):1783-1792.

[86]RobinsonP, KasembeliM, BharadwajU, et al., 2016. Substance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistance. Biomed Res Int, 2016:1959270.

[87]RoosC, DahlgrenD, BergS, et al., 2017. In vivo mechanisms of intestinal drug absorption from aprepitant nanoformulations. Mol Pharm, 14(12):4233-4242.

[88]RouenPA, WhiteML, 2018. Dry eye disease: prevalence, assessment, and management. Home Healthc Now, 36(2):74-83.

[89]ShiY, WangX, MengY, et al., 2021. A novel mechanism of endoplasmic reticulum stress- and c-Myc-degradation-mediated therapeutic benefits of antineurokinin-1 receptor drugs in colorectal cancer. Adv Sci (Weinh), 8(21):e2101936.

[90]SchöppeJ, EhrenmannJ, KlenkC, et al., 2019. Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists. Nat Commun, 10:17.

[91]SinghS, KumaravelS, DholeS, et al., 2021. Neuropeptide substance P enhances inflammation-mediated tumor signaling pathways and migration and proliferation of head and neck cancers. Indian J Surg Oncol, 12 (S1):93-102.

[92]SmithJA, HarleA, DockryR, et al., 2021. Aprepitant for cough in lung cancer. A randomized placebo-controlled trial and mechanistic insights. Am J Respir Crit Care Med, 203(6):737-745.

[93]SosnikA, SeremetaKP, 2015. Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers. Adv Colloid Interface Sci, 223:40-54.

[94]SteinhoffMS, von MentzerB, GeppettiP, et al., 2014. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev, 94(1):265-301.

[95]SuganoK, TeradaK, 2015. Rate- and extent-limiting factors of oral drug absorption: theory and applications. J Pharm Sci, 104(9):2777-2788.

[96]TaketaniY, DohlmanT, ChenYH, et al., 2019. Restoration of regulatory T cell function in dry eye disease by targeting substance P/neurokinin 1 receptor. Invest Ophthalmol Vis Sci, 60(9):306.

[97]TangYJ, LiuJJ, ZhangDY, et al., 2020. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol, 11:1708.

[98]TattersallFD, RycroftW, FrancisB, et al., 1996. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology, 35(8):1121-1129.

[99]ThomC, EhrenmannJ, VaccaS, et al., 2021. Structures of neurokinin 1 receptor in complex with Gq and Gs proteins reveal substance P binding mode and unique activation features. Sci Adv, 7(50):eabk2872.

[100]UnH, UganRA, KoseD, et al., 2020. A novel effect of Aprepitant: protection for cisplatin-induced nephrotoxicity and hepatotoxicity. Eur J Pharmacol, 880:173168.

[101]WanPX, SuWR, ZhangYY, et al., 2020. LncRNA H19 initiates microglial pyroptosis and neuronal death in retinal ischemia/reperfusion injury. Cell Death Differ, 27:176-191.

[102]WangXL, HeY, MackowiakB, et al., 2021. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut, 70(4):784-795.

[103]WidiapradjaA, ManteufelEJ, DehlinHM, et al., 2019. Regulation of cardiac mast cell maturation and function by the neurokinin-1 receptor in the fibrotic heart. Sci Rep, 9:11004.

[104]WuHZ, ChengXE, HuangFY, et al., 2020. Aprepitant sensitizes acute myeloid leukemia cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Drug Des Devel Ther, 14:2413-2422.

[105]YamamotoH, 1993. Preserved endothelial function in the spastic segment of the human epicardial coronary artery in patients with variant angina—role of substance P in evaluating endothelial function. Eur Heart J, 14(Suppl I):118-122.

[106]YanaiR, NishidaT, HatanoM, et al., 2020. Role of the neurokinin-1 receptor in the promotion of corneal epithelial wound healing by the peptides FGLM-NH2 and SSSR in neurotrophic keratopathy. Invest Ophthalmol Vis Sci, 61(8):29.

[107]YangY, ZhouW, XuXQ, et al., 2021. Aprepitant inhibits JNK and p38/MAPK to attenuate inflammation and suppresses inflammatory pain. Front Pharmacol, 12:811584.

[108]YeoS, AnJ, ParkC, et al., 2020. Design and characterization of phosphatidylcholine-based solid dispersions of aprepitant for enhanced solubility and dissolution. Pharmaceutics, 12(5):407.

[109]ZhangXW, XingHJ, ZhaoY, et al., 2018. Pharmaceutical dispersion techniques for dissolution and bioavailability enhancement of poorly water-soluble drugs. Pharmaceutics, 10(3):74.

[110]ZhangXW, LiL, HuWQ, et al., 2022. Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR. Cell Death Dis, 13:41.

[111]ZhaoXN, BaiZZ, LiCH, et al., 2020. The NK-1R antagonist aprepitant prevents LPS-induced oxidative stress and inflammation in RAW264.7 macrophages. Drug Des Devel Ther, 14:1943-1952.

Open peer comments: Debate/Discuss/Question/Opinion


Please provide your name, email address and a comment

Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE